RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 62 filers reported holding RA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $294,724,000 | +2.3% | 6,138,797 | 0.0% | 15.40% | +13.0% |
| Q4 2019 | $288,094,000 | +98.4% | 6,138,797 | 0.0% | 13.62% | +13.3% |
| Q3 2019 | $145,183,000 | -21.4% | 6,138,797 | 0.0% | 12.02% | -7.0% |
| Q2 2019 | $184,594,000 | +34.2% | 6,138,797 | 0.0% | 12.93% | +81.1% |
| Q1 2019 | $137,509,000 | +23.1% | 6,138,797 | 0.0% | 7.14% | +61.1% |
| Q4 2018 | $111,726,000 | +12.4% | 6,138,797 | +11.7% | 4.43% | +3.3% |
| Q3 2018 | $99,380,000 | +81.8% | 5,493,636 | 0.0% | 4.29% | +67.4% |
| Q2 2018 | $54,662,000 | +87.4% | 5,493,636 | 0.0% | 2.56% | +97.3% |
| Q1 2018 | $29,171,000 | -1.8% | 5,493,636 | +57.2% | 1.30% | +5.5% |
| Q4 2017 | $29,696,000 | -41.8% | 3,493,636 | 0.0% | 1.23% | -31.2% |
| Q3 2017 | $51,007,000 | -22.1% | 3,493,636 | 0.0% | 1.79% | -25.0% |
| Q2 2017 | $65,471,000 | -12.0% | 3,493,636 | 0.0% | 2.38% | -7.9% |
| Q1 2017 | $74,380,000 | +40.2% | 3,493,636 | 0.0% | 2.59% | +22.6% |
| Q4 2016 | $53,068,000 | – | 3,493,636 | – | 2.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |